In medical device development, the PM's responsibilities definitely expand beyond traditional management, but I would not say they shift completely away from it. Instead, I think compliance assurance is embedded in task management itself, as the DHF is not just documentation but also objective evidence that the developed device is in accordance with regulatory requirements/design controls. For example, linking design outputs to user needs, predefining verification/validation activities, and documenting risk management matrices become critical milestones for management in addition to compliance. In such a way, initiating and planning start to entail the integration of elements of traceability and risk mitigation while also ensuring alignment with FDA expectations. Thus, key compliance-based deliverables essentially help guide project execution and management. Based on this discussion, I was wondering if you think organizations sometimes underestimate how early regulatory thinking must be integrated into planning?

The idea of balancing between the PM's responisbility to provide a product to marktet and properly managing the compliance of the DHF is something I have considered as well. My initial thought is, priority should stand on properly managing the FDA compliance assurances, since without FDA approval the product can never go to market to begin with. However, after reading Krish's response, I tend to agree with him that the processes are more intertwined than I had initially thought. In the PM's management of the DHF, they are intrinsically ensuring that the tasks needed for the physical development of the project are being completed. The DHF and managing the needs of the regulatory organizations, as well as the management and development of the product itself or closely tied together and ultimately result in the product being brought to market and sold. 

I agree with Krish that the PM's role combines task management with the objective of completing the DHF and compliance assurance. While the PM shouldn't be the only one focused on compliance, when trying to get a medical device to market, FDA compliance is a very important requirement. However, the PM's job goes beyond just the scope of compliance and quality management. As the DHF is extremely important, in line with what cra24 suggested, it can be a valuable tool in guiding the flow of the project. A large part of a PM's job, as discussed in previous forum posts, lies outside the direct scope of the project's files because the PM must also oversee the people on the team, related to the project, and their progress and the potential risks to them. This would fall under the scope of traditional management. I think it depends on the situation at hand and the project team for which type of management (traditional or compliance/deliverable-driven) a PM falls under at any given moment. It is wise to strike a balance of the two and have each style inform the other. If you, as a PM, are only driven to produce a DHF for compliance purposes, you may overlook other vital aspects of the project. 

I agree that the PM’s role doesn’t fully shift to compliance, but I do think the mindset shifts. In medical device development, compliance isn’t a separate workstream but it becomes the framework within which everything else operates. To me, the PM’s responsibility becomes less about managing tasks and more about managing risk visibility. If traceability, verification planning, and regulatory strategy are built into the schedule from the start, then getting to market and maintaining compliance move in parallel.

I also think strong PMs avoid the false trade-off between speed and compliance by asking, "what would an auditor question here?" Designing with that lens from day one may actually prevent delays later.

Do you think most delays in medical device projects come from poor execution, or from regulatory considerations being integrated too late?

I agree with Krish, a DHF is evidence that the developed device meets regulatory requirements. I would like to add a different perspective as well. It is also worthwhile to question if a DHF is actually the PM's major deliverable or if there is more at hand. In other words, it is critical to consider whether the decision performance a PM makes is always under regulatory constraints. In a team, one must make rational and risk informed decisions, and the PM's responsibility is not to shift from just task management to compliance. A PM should evolve into a leadership style of decision making with integrity. At some point, completing tasks is not enough to deliver documented and controlled outputs. Therefore the objective is not just compliance instead, it is the fruit of the structure of a project.
A PM working on a medical device team is driven less by tasks and more by amplifying risk, since DHF includes traceability, hazard analysis, and mitigation efforts. A PM has to ensure that the risks are visible early on. If the risks are brought up too late, then there can be adverse effects when regulatory findings or recalls occur. Compliance is not just paperwork but organization and liability protection.
It is essential to question if most medical device delays are from poor documentation or are commonly due to deep issues like unclear user needs that the DHF brings to light?

Poor execution and late regulatory integration are both common pitfalls for medical device developers. Startups are likely to design medical devices with a strong emphasis on innovation, and risk integrating regulatory compliance later than necessary. This can be an example of the need to prioritize compliance assurance and risk management early in the process rather than managing design tasks. However, I do agree that the project manager's responsibilities are connected, emphasizing the need for PM software and templates. Key points, such as determining the medical device class and transitioning phases with proper inputs and outputs, are what the project manager needs to control to prevent the project from failing. 

@aca your challenging of the idea that the DHF is the PM's ultimate deliverable. If a PM's mindset becomes to produce a perfect DHF, they risk placing too much focus on compliance instead of acting as a proper strategic leader. The real deliverable isn't the DHF itself, its a safe, effective, defensible device, and the DHF is the structured proof of that outcome. While many decisions are made under regulatory constraints, those constraints don't eliminate judgment, they heighten its importance. a PM must create an environment where risks are made visible early, not buried until verification or audit stages expose them. Your point on compliance is very strong as well, as compliance is a combination of liability protection and is proof of strong organizational discipline. 
I do have one question for you however, if a PM's responsibility is to amplify risk visibility and ensure decisions are rational and data-driven, how should they act when business leadership pushes forward despite unresolved risk signals, as you mentioned that the DHF should be what results from a strong project structure rather than the central objective itself as that shifts focus from documentation compliance to decision integrity. 

The PM's role does not fully shift from taskmanagement to compliance, but in medical device development, the two could become inseparable. Every task should generate objective evidence that feeds into the DHF, so managing activities and ensuring compliance occur in parallel. Although, the real deliverable is not just a "perfect DHF," but a safe and effective device that is defensible. The DHF is the structured prroof that the best decisions were indeed made. Additionally. balancing the speed to market with compliance comes down to early integration. If regulatory strategy, traceability, and risk analysis are embedded in initiating and planning, compliance supports progress instead of slowing it down. Additional delays occur not because of strict compliance, but more so because of regulatory thinking that was introduced too late that exposes underlying gaps.

I really like the point that the DHF isn’t the true deliverable, but rather the evidence of sound decision-making. I don’t think the PM’s role shifts away from task management, but instead, task management becomes compliance-informed by default. In medical device development, every timeline decision, design review, and risk discussion has regulatory implications, so the PM is constantly thinking one step ahead about traceability and defensibility. I also think the balance between speed and compliance comes down to integration; if risk management and regulatory strategy are built into the schedule from day one, they don’t feel like obstacles later. When compliance is treated as a parallel process instead of a final checkpoint, getting to market and meeting FDA expectations can actually reinforce each other rather than compete.

In medical device development, I would argue that the PM’s responsibility doesn’t fully shift from task management to compliance assurance, but rather that compliance becomes inseparable from execution. Because the Design History File (DHF) captures the Design Development Plan, risk management activities, verification and validation evidence, and full traceability of requirements to design outputs, it effectively becomes proof that the device was developed in accordance with FDA design control requirements. In this environment, undocumented work is essentially work that did not occur from a regulatory standpoint, so timelines, milestones, and deliverables must be structured around compliance checkpoints. The PM therefore operates not just as a scheduler of activities, but as an integrator of regulatory, quality, and engineering functions—ensuring that risk mitigation strategies are implemented and documented, design reviews are conducted properly, and all outputs align with established requirements. Balancing speed to market with meticulous compliance comes down to integration rather than sequencing; when regulatory strategy and risk management are embedded early during initiation and planning, compliance reduces downstream rework and ultimately supports faster, more sustainable commercialization rather than delaying it.